老带新
RecombiMAb anti-mouse PD-1 (CD279) (D265A)
1/2

RecombiMAb anti-mouse PD-1 (CD279) (D265A)

分享
品牌: BioXcell
pdf 下载产品说明书
pdf 下载SDS
用小程序,查商品更便捷
收藏
对比对比
咨询咨询
产品介绍
产品介绍
产品信息

Product Details

The 29F.1A12™-CP005 monoclonal antibody is a recombinant chimeric version of the original 29F.1A12™ antibody. The variable domain sequences are identical to the original 29F.1A12™ but the constant region sequences have been switched from rat IgG2a to mouse IgG1. The 29F.1A12™-CP005 antibody also contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. 29F.1A12™-CP005 reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments.

Specifications

Isotype Mouse IgG1, κ
Recommended Isotype Control(s)RecombiMAb mouse IgG1 (D265A) isotype control, anti-hen egg lysozyme
Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer
Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Mutations D265A
Immunogen Recombinant PD-1-Ig fusion protein
Reported Applicationsin vivo blocking of PD-1/PD-L signaling*
in vitro PD-1 neutralization*
Immunohistochemistry (frozen)*
Immunofluorescence*
Western blot*
Flow cytometry*
*Reported for the original rat IgG2a 29F.1A12 antibody
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <1EU/mg (<0.001EU/μg)
Determined by LAL gel clotting assay
Aggregation <5%
Determined by SEC
Purity >95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from HEK293 cell supernatant in an animal-free facility
Purification Protein G
Molecular Weight 150 kDa
Murine Pathogen Tests Ectromelia/Mousepox Virus: Negative
Hantavirus: Negative
K Virus: Negative
Lactate Dehydrogenase-Elevating Virus: Negative
Lymphocytic Choriomeningitis virus: Negative
Mouse Adenovirus: Negative
Mouse Cytomegalovirus: Negative
Mouse Hepatitis Virus: Negative
Mouse Minute Virus: Negative
Mouse Norovirus: Negative
Mouse Parvovirus: Negative
Mouse Rotavirus: Negative
Mycoplasma Pulmonis: Negative
Pneumonia Virus of Mice: Negative
Polyoma Virus: Negative
Reovirus Screen: Negative
Sendai Virus: Negative
Theiler’s Murine Encephalomyelitis: Negative
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
声明 :本官网所有报价均为常温或者蓝冰运输价格,如有产品需要干冰运输,需另外加收干冰运输费。
货号:
CP005-5MG
一键复制
询价
5 mg
25 mg
选择数量
当前规格1件起购 
配送至
预计2-3周送达,快递: 免运费,若需干冰额外收费